Objectives: To evaluate the performance of the Accelerate Pheno TM system for the identification and antimicrobial susceptibility testing (AST) of a panel of Gram-negative bacilli (GNB) with different resistance profiles (e.g. penicillinases, ESBLs, cephalosporinase overproduction, carbapenemases, impermeability) directly from positive blood cultures in ,7 h.
Introduction
The incidence of bloodstream infections (BSIs) is reported to be 150 per 100000 population. 1 In ICUs, the incidence is 30% of admissions, a level that has remained stable over the last decade. 1, 2 Septic shock, the most severe form of sepsis, occurs in 10%-20% of ICU-admitted patients. 1, 3 It is responsible for increases in both length of stay and healthcare-related costs. 4, 5 Moreover, BSIs are a leading cause of death in critically ill patients worldwide, with an overall mortality rate of close to 40%. 6, 7 The spread of MDR Gram-negative bacilli (GNB) has become a major public health challenge directly related to the misuse and overuse of antibiotics. 8 The rapid optimization of antibiotic therapy, according to the organism and its resistance profile, is a major goal both for individual patients and for public health. 9 In severe sepsis and septic shock, the importance of early appropriate treatment is crucial, given the linear increase in the risk of mortality with each hour for which antibiotic administration is delayed. 10 Current clinical microbiology methods are time consuming and are not validated for direct use on positive blood cultures. These methods require an overnight pure subculture on agar for subsequent identification of causative organisms and preparation of a standard inoculum for antimicrobial susceptibility testing (AST) according to the manufacturer's guidelines. Faster identification and AST directly from positive blood cultures would have the potential to significantly improve time to diagnosis and initiation of appropriate antibiotic and patient management in ICUs. However, to our knowledge, none of the current technologies provide prompt AST with MICs that truly reflect the resistance profile of the bacteria involved in the BSI. In this study, we evaluated the performance of the Accelerate Pheno TM system (Accelerate Diagnostics Inc.) compared with routine laboratory analysis in order: (i) to provide a correct identification in 1.5 h; and (ii) to detect resistance in a panel of GNB, representative of the ecology of our region, within 7 h.
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Methods
Bacterial panel
A panel of 105 clinical GNB isolates belonging to a collection from our Regional MDR GNB Reference Lab (the CARB-LR group) 13, 14 in the Occitanie Region was tested (Table 1) . Ninety-nine Enterobacteriaceae isolates were included with the following distribution: Escherichia coli (n " 36), Klebsiella pneumoniae (n " 34), Enterobacter cloacae (n " 14), Enterobacter aerogenes (n " 5), Klebsiella oxytoca (n " 5), Citrobacter freundii (n " 2), Citrobacter koseri (n " 2) and Proteus mirabilis (n " 1). Different b-lactam resistance profiles were selected with the following properties: (i) susceptibility to third-generation cephalosporins (3GC-S, n " 23); (ii) resistance to 3GCs (3GC-R, n " 26) mediated by ESBL (n " 17) or overexpressed/ plasmid-mediated cephalosporinases (AmpC, n " 9); and (iii) resistance to carbapenems (n " 50) involving carbapenemase production (n " 33) or membrane permeability alterations (n " 17). Six Acinetobacter baumannii strains were also included: a wild-type phenotype (n " 1), and different carbapenemase-producing isolates [OXA-23, -24 or -58-type producers (n " 5)].
Isolates had been previously identified using the VITEK V R MS and VITEK V R 2 systems (bioMérieux, France). Susceptibility to antimicrobial agents was tested by the disc-diffusion method (BioRad, Marnes La Coquette, France) on Mueller-Hinton agar according to EUCAST-SFM 2016 recommendations (http://www.sfm-microbiologie.org). In addition, the MICs of carbapenems (ertapenem and meropenem) were determined by the Etest V R method (bioMérieux). The MIC of colistin was determined using microbroth dilution (Umic V R , Biocentric, France). The MICs were interpreted as specified by the EUCAST-SFM criteria. All isolates were typed by Check-MDR CT102/103 V R microarrays (Check-point, the Netherlands). Confirmation of the presence of b-lactamase-encoding genes was done by PCRs using specific primers and confirmed by sequencing the PCR products as previously described. [15] [16] [17] [18] [19] Emerging resistance mechanisms (colistin resistance mcr-1 determinant and 16S rRNA methylase) were also characterized by PCR as previously described. 20, 21 The AST results of the studied strains are presented in Table S1 (available as Supplementary data at JAC Online).
Sample preparation
For each isolate, 100 cfu was spiked into sterile blood culture bottles [BD BACTEC TM Plus Aerobic/F and BD BACTEC TM Lytic/10 Anaerobic/F (BD Diagnostics)] containing 10 mL of fresh blood. Blood cultures were incubated in a BACTEC TM FX automated blood culture device until they flagged positive for microbial growth. All positive blood cultures were divided into two samples: (i) 1 mL for conventional comparator methods; and (ii) 0.5 mL for the Accelerate Pheno TM system.
Conventional comparator methods
All positive blood cultures were subcultured on blood agar plates (bioMérieux) for 18-24 h at 37+2 C. Species-level identification was performed on isolated colonies by the VITEK V R MS and VITEK V R 2 systems. These methods were used as the comparators for bacterial identification. AST was determined by the agar disc-diffusion method according to EUCAST-SFM recommendations. Etest V R (bioMérieux) was used to obtain MIC values for antibiotics included on the Accelerate Pheno TM system panel.
The results of disc diffusion (and Etest V R for carbapenems, colistin and all discrepant results) were used as the comparator for AST.
Accelerate PhenoTest TM BC kit testing
Accelerate PhenoTest TM BC kits were run on a two-module Accelerate Pheno TM system using software version 1.2.0.87. As recommended by the manufacturer, all positive blood cultures were tested within 8 h after the blood culture bottle flagged positive. A 500 lL sample of blood was introduced into the sample vial and loaded into the Accelerate Pheno TM system according to the manufacturer's instructions. This system uses cocktails of fluorescently labelled oligonucleotide probes and in situ hybridization to identify bacterial species, and morphokinetic cellular analysis to measure distinct morphokinetic features (cell morphology, mass, division rate) of live microbial cells responding to antimicrobials to generate susceptibility results. An algorithm converts bacterial growth or inhibition in the presence of an antibiotic into an MIC value.
Statistical analysis
For identification, the Accelerate Pheno TM system results were compared with results from the VITEK V R MS and VITEK V R 2 systems. For AST, the Accelerate Pheno TM system results were compared with results from discdiffusion and Etest V R methods. Ampicillin/sulbactam was not evaluated in this study because this antibiotic is not used in France.
The percentage of errors between comparator methods and the Accelerate Pheno TM system was evaluated. If a discrepant result was observed between the Accelerate Pheno TM system and Etest V R , the two tests were repeated twice to rule out experimental error. If a concordant result [susceptible (S), intermediate (I) or resistant (R)] was obtained in two of the three test results, this result was considered correct. The total category agreement was determined and the discrepancies were categorized as follows: very major error (VME; false susceptibility by the Accelerate Pheno TM system), major error (ME; false resistance by the Accelerate Pheno TM system) and minor error (mE; I result reported by one method and S or R reported by the other method). The VME rate was expressed: (i) as the number of all VMEs detected between the system and culture-based AST out of the total number of MICs determined; (ii) as all the discrepant results detected between the system (reported S) and culture-based AST (reported I or R) out of the number of resistant strains for the tested antibiotics. The ME rate was expressed: (i) as the number of all MEs detected between the system and culture-based AST out of the total number of MICs determined; (ii) as all the discrepant results detected between the system (reported I or R) and culture-based AST (reported S) out of the number of susceptible strains for the tested antibiotics.
Results and discussion
Our evaluation of the Accelerate Pheno TM system assessed the potential for correct identification of bacterial genus. In the panel we studied, the Accelerate Pheno TM system exhibited 100% identification agreement with the VITEK V R MS and VITEK V R 2 systems. An analysis of the bacterial ecology of our university hospital in 2016 showed that the panel of aerobic GNB detected by this instrument (E. coli, Klebsiella spp., Enterobacter spp., Proteus spp., Citrobacter spp., Serratia marcescens, Pseudomonas aeruginosa and A. baumannii) represented 87.1% (590/677) and 93.6% (573/612) of aerobic GNB isolated in aerobic and anaerobic bottles, respectively (personal data). The Accelerate Pheno TM system accurately identified the main pathogens involved in BSIs. Moreover, as the result is reported in ,1.5 h, it shows a clear advantage compared with routine laboratory procedures and is similar in speed to other solutions (e.g. Biofire V R Film Array, Verigene V R Nanosphere). Regarding the AST results from the panel studied here, the Accelerate Pheno TM system generated AST data for all of the tested samples. A total of 1232 AST results were produced and Accelerate Pheno TM system and Gram-negative bacilli JAC 
AmpC hyperproduction (5) AmpC hyperproduction, CTX-M-group 9 (1) AmpC hyperproduction, SHV One CTX-M-producing E. coli harboured the plasmid-mediated colistin resistance gene mcr-1 (colistin MIC 4 mg/L). c Two KPC-producing K. pneumoniae harboured the aminoglycoside resistance methyltransferase gene armA.
Pantel et al. Accelerate Pheno TM system and Gram-negative bacilli JAC compared with disc-diffusion (S, I, R) and Etest V R results. The overall category agreement between the Accelerate Pheno TM system and culture-based AST was 94.9% (1169/1232). Error rates were as follows: mE, 4.1% (51/1232); ME, 0.3% (4/1232); and VME, 0.7% (8/1232). After removing the bias of the prevalence of R and S strains in our panel, these error rates were: ME, 3.9% (26/668) and VME, 3.9% (22/564). The results are shown in Tables 2-4 .
The highest number of discrepancies occurred for aztreonam (11.1%) and cefepime (15.2%) ( Table 2) . For aztreonam, all the discrepant results corresponded to mEs in Enterobacteriaceae irrespective of the b-lactamase resistance profile. For cefepime, 14 mEs were observed, equally distributed among the resistance profiles, and two VMEs were detected in one ESBL-producing K. pneumoniae and one NDM-producing E. aerogenes (Table 4) . However, aztreonam and cefepime are not used for first-line management of either sepsis or septic shock. 22 The other minor errors were equally distributed among the different isolates of our panel irrespective of resistance profile (Table 2) . Interestingly, some discrepant results were observed for cephalosporinaseoverproducing isolates, with two isolates considered S instead of I for ceftazidime. However, in these two isolates, the ceftriaxone MICs were categorized as R by the Accelerate Pheno TM system, which allowed the isolates to be considered R to 3GC. In the same way, we observed two errors among ESBL-producers, with a VME and an ME in the ceftazidime results from two CTX-M-producing E. coli isolates (Table 4 ). In these two cases, however, if we use an interpretative reading of the AST results (which enables the possible mechanism of resistance expressed by the bacteria to be deduced), 23 the ceftriaxone MIC results indicate the possibility of an ESBL with a clear resistance profile consistent with cefotaximase producers.
More importantly, we observed VMEs [0.5% (3/564) and 0.2% (1/564) for ertapenem and meropenem, respectively] or MEs [0.2% (1/668) for meropenem] in the carbapenem results of five carbapenem-resistant Enterobacteriaceae. Three of the five discrepancies were noted for class B metallo-b-lactamases (two NDM-and one VIM-type producer) ( Table 4 ). In these three cases, the susceptible meropenem result did not allow for correction of the false-susceptible ertapenem result. This could result in inappropriate therapeutic management of patients. In contrast, the results of two other cases of an ME and a VME with meropenem (due to impermeability and IMI production, respectively) could be called into question based on ertapenem MIC results which could have guided antibiotic treatment.
Overall, 3/14 class B carbapenemase-producing Enterobacteriaceae showed discrepant results for ertapenem, with two VMEs out of ten NDM-producers and one VME out of four VIM-producers. One hypothesis to explain these results is that the discrepancies could be related to the zinc concentration of the medium used for bacterial growth. Zinc enables complete expression of the metallo-b-lactamases, which are known to use zinc ions in their catalytic sites. 24, 25 In 3GC-S strains, only one VME was observed for piperacillin/tazobactam with K. pneumoniae. By species, the major discrepant results (VMEs and MEs) were observed with E. coli (n " 6), Klebsiella spp. (n " 3) and Enterobacter spp. (n " 2) ( Table 4) . Only one isolate (NDM-producing E. aerogenes) produced two VMEs (0.9% of the studied panel). On the other hand, no MEs or VMEs for Citrobacter spp., Proteus spp. or A. baumannii were observed, irrespective of the resistance profile, though only small Pantel et al.
numbers of strains were tested in these species. Furthermore, isolates harbouring emerging co-resistant determinants (one MCR-1-producing E. coli and two armA-producing K. pneumoniae) produced correct AST results. Some limitations of this study should be noted. The number of susceptible strains was limited for some antibiotics. Moreover, the panel of studied strains was representative of the MDR organisms actually observed in France and was not exhaustive. However, the aim of our study was to focus on the potential of the Accelerate Pheno TM system to detect these local MDR bacteria. Early susceptibility results are crucial for the initiation of appropriate antimicrobial therapy for critically ill patients, including those in settings challenged by MDR bacteria, such as ICUs. Failure to initiate appropriate empirical therapy in patients with sepsis and septic shock is associated with a substantial increase in morbidity and mortality. 22 To date, no tool gives a phenotypic AST result in ,7 h directly from specimens such as positive blood cultures. Three recent studies by Marschal et al., 12 Brazelton de Cá rdenas et al. 26 and Charnot-Katsikas et al. 27 have demonstrated the performance of the Accelerate Pheno TM system in a routine diagnostic setting. However, owing to the scarcity of MDR bacteria, these studies have not challenged the instrument on a large characterized panel of MDR GNB. In this study, we demonstrated the high performance of a new technology to obtain fast identification and AST results directly from positive blood cultures. This system may enable clinicians to adjust antimicrobial treatment earlier to facilitate patient management and outcomes as well as antimicrobial stewardship. 
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